Bloomberg Intelligence: Pharma Bidding Wars, AI Chip Demand, and Tyson Foods Outlook

Pharmaceutical Bidding Wars and Obesity Drugs

• 💊 Metsera shares tumbled after Novo Nordisk declined to increase its offer, ending a bidding war with Pfizer.
• 💡 The FTC flagged potential regulatory risks with the Novo deal structure, influencing Metsera's decision.
• 🎯 Sam Fazeli notes that Metsera's experimental weight-loss drug has a similar side effect profile to other GLP-1s, with nausea and vomiting being common early side effects.
• 📈 The obesity market is a key focus for pharmaceutical companies, with Eli Lilly currently well-positioned due to its existing assets.

AI Chip Demand and TSMC's Role

• ⚡ Mandeep Singh discusses Taiwan Semiconductor Manufacturing Co. (TSMC) reporting slower sales growth, attributing it partly to a shift in spending towards AI, impacting non-AI hardware.
• 🚀 Despite a slowdown in monthly sales, TSMC's AI segment is projected for significant growth, with Nvidia CEO Jensen Huang requesting more chip supplies due to strong AI demand.
• ⚠️ While Intel aims to revive its manufacturing capabilities, TSMC currently holds an